Shift in phenotypic susceptibility suggests a competition mechanism in a case of acquired resistance to maraviroc

被引：9

作者：

Delobel, Pierre ^{[2
,3
,4
]}

Raymond, Stephanie ^{[1
,2
,3
]}

Mavigner, Maud ^{[2
]}

Cazabat, Michelle ^{[1
,2
]}

Alvarez, Muriel ^{[4
]}

Marchou, Bruno ^{[3
,4
]}

Massip, Patrice ^{[3
,4
]}

Izopet, Jacques ^{[1
,2
,3
]}

机构：

[1] CHU Toulouse, Hop Purpan, Virol Lab, F-31300 Toulouse, France

[2] Fac Med Toulouse, INSERM, U563, F-31073 Toulouse, France

[3] Univ Toulouse III Paul Sabatier, Ctr Physiopathol Toulouse Purpan, Toulouse, France

[4] CHU Toulouse, Hop Purpan, Serv Malad Infect & Trop, F-31300 Toulouse, France

来源：

AIDS | 2010年 / 24卷 / 09期

关键词：

CCR5;

D O I：

10.1097/QAD.0b013e328338b7a6

中图分类号：

R392 [医学免疫学]; Q939.91 [免疫学];

学科分类号：

100102 ;

摘要：

引用

页码：1382 / 1384

页数：3

共 10 条

[1]

Bjorndal A, 1997, J VIROL, V71, P7478

[2] Maraviroc (UK-427,857), a potent, orally bioavailable, and selective small-molecule inhibitor of chemokine receptor CCR5 with broad-spectrum anti-human immunodeficiency virus type 1 activity [J].

Dorr, P ;

Westby, M ;

Dobbs, S ;

Griffin, P ;

Irvine, B ;

Macartney, M ;

Mori, J ;

Rickett, G ;

Smith-Burchnell, C ;

Napier, C ;

Webster, R ;

Armour, D ;

Price, D ;

Stammen, B ;

Wood, A ;

Perros, M .

ANTIMICROBIAL AGENTS AND CHEMOTHERAPY, 2005, 49 (11) :4721-4732

[3] Maraviroc for previously treated patients with R5 HIV-1 infection [J].

Gulick, Roy M. ;

Lalezari, Jacob ;

Goodrich, James ;

Clumeck, Nathan ;

DeJesus, Edwin ;

Horban, Andrzej ;

Nadler, Jeffrey ;

Clotet, Bonaventura ;

Karlsson, Anders ;

Wohlfeiler, Michael ;

Montana, John B. ;

McHale, Mary ;

Sullivan, John ;

Ridgway, Caroline ;

Felstead, Steve ;

Dunne, Michael W. ;

van der Ryst, Elna ;

Mayer, Howard .

NEW ENGLAND JOURNAL OF MEDICINE, 2008, 359 (14) :1429-U27

[4]

Lewis M, 2008, 15 C RETR OPP INF BO

[5]

MORI J, 2007, 16 INT HIV DRUG RES

[6] HIV-1 clones resistant to a small molecule CCR5 inhibitor use the inhibitor-bound form of CCR5 for entry [J].

Pugach, Pavel ;

Marozsan, Andre J. ;

Ketas, Thomas J. ;

Landes, Elissa L. ;

Moore, John P. ;

Kuhmann, Shawn E. .

VIROLOGY, 2007, 361 (01) :212-228

[7] Development and performance of a new recombinant virus phenotypic entry assay to determine HIV-1 coreceptor usage [J].

Raymond, Stephanie ;

Delobel, Pierre ;

Mavigner, Maud ;

Cazabat, Michelle ;

Souyris, Corinne ;

Encinas, Stephanie ;

Bruel, Patrick ;

Sandres-Saune, Karine ;

Marchou, Bruno ;

Massip, Patrice ;

Izopet, Jacques .

JOURNAL OF CLINICAL VIROLOGY, 2010, 47 (02) :126-130

[8] Emergence of CXCR4-Using human immunodeficiency virus type 1 (HIV-1) variants in a minority of HIV-1-Infected patients following treatment with the CCR5 antagonist maraviroc is from a pretreatment CXCR4-using virus reservoir [J].

Westby, M ;

Lewis, M ;

Whitcomb, J ;

Youle, M ;

Pozniak, AL ;

James, IT ;

Jenkins, TM ;

Perros, M ;

van der Ryst, E .

JOURNAL OF VIROLOGY, 2006, 80 (10) :4909-4920

[9] Reduced maximal inhibition in phenotypic susceptibility assays indicates that viral strains resistant to the CCR5 antagonist maraviroc utilize inhibitor-bound receptor for entry [J].

Westby, Mike ;

Smith-Burchnell, Caroline ;

Mori, Julie ;

Lewis, Marilyn ;

Mosley, Michael ;

Stockdale, Mark ;

Dorr, Patrick ;

Ciaramella, Giuseppe ;

Perros, Manos .

JOURNAL OF VIROLOGY, 2007, 81 (05) :2359-2371

[10] Development and characterization of a novel single-cycle recombinant-virus assay to determine human immunodeficiency virus type 1 coreceptor tropism [J].

Whitcomb, Jeannette M. ;

Huang, Wei ;

Fransen, Signe ;

Limoli, Kay ;

Toma, Jonathan ;

Wrin, Terri ;

Chappey, Colombe ;

Kiss, Linda D. B. ;

Paxinos, Ellen E. ;

Petropoulos, Christos J. .

ANTIMICROBIAL AGENTS AND CHEMOTHERAPY, 2007, 51 (02) :566-575

← 1 →